We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Specialized Nuclear Bodies Delay and Promote Repair of DNA Damage

By LabMedica International staff writers
Posted on 14 Mar 2019
A molecular mechanism that helps minimize the impact of natural DNA errors, which occur during the process of cell division and replication, was identified and characterized in cultures of human cells.

Failure to complete DNA replication is a by-product of genome doubling in almost every cell cycle. More...
During mitosis, under-replicated DNA (UR-DNA) is converted into DNA lesions, which are inherited by daughter cells and sequestered in 53BP1 nuclear bodies (53BP1-NBs).

The fate of DNA with unresolved replication intermediates is not known. Previous studies showed that mild replication stress increased the frequency of chromosomal lesions that were transmitted to daughter cells. Throughout G1, these lesions were sequestered in nuclear compartments marked by p53-binding protein 1 (53BP1) and other chromatin-associated genome caretakers. The number of such 53BP1 nuclear bodies increased after genetic ablation of BLM, a DNA helicase associated with dissolution of entangled DNA. Conversely, 53BP1 nuclear bodies were partially suppressed by knocking down SMC2, a condensin subunit required for mechanical stability of mitotic chromosomes. In addition, 53BP1 nuclear bodies protected chromosomal fragile sites sequestered in these compartments against erosion.

In the current study, which was published in the February 25, 2019, online edition of the journal Nature Cell Biology, investigators at the University of Copenhagen (Denmark) showed that the formation of 53BP1-NBs interrupted the chain of repetitive damage intrinsically embedded in UR-DNA. This result was obtained by labeling 53BP1-NBs in living human cells using fluorescent dyes and then following them under a microscope over several successive generations. Using this method, the investigators traced the fate of inherited DNA damage directly from the time of generation in mother cells to their final destiny in daughter cells.

The investigators found that unlike clastogen-induced 53BP1 foci that were repaired throughout interphase, 53BP1-NBs restrained replication of the embedded genomic loci until late S phase, thus enabling the dedicated RAD52-mediated repair of UR-DNA lesions. A clastogen is a mutagenic agent giving rise to or inducing disruption or breakages of chromosomes, leading to sections of the chromosome being deleted, added, or rearranged. RAD52 is a protein that plays a central role in genetic recombination and DNA repair by promoting the annealing of complementary single-stranded DNA and by stimulation of the RAD51 recombinase.

The absence or malfunction of 53BP1-NBs caused premature replication of the affected loci, accompanied by genotoxic RAD51-mediated recombination (a genotoxic agent is a chemical or another agent that damages cellular DNA, resulting in mutations or cancer). Thus, by adjusting replication timing and repair pathway choice at under-replicated loci, 53BP1-NBs enabled the completion of genome duplication of inherited UR-DNA and prevented the conversion of under-replications into genome instability.

"53BP1 nuclear bodies delay cell division in daughter cells in order to reach the only remaining time in their lifecycle when they can mend DNA lesions that their mother caused but could not fix. This second chance is vital because it is also the last one. We have predicted and then experimentally documented that a failure of this second chance converts the initially curable DNA damage to one that can no longer be fixed. Accumulation of such mishaps could lead to disease, including cancer", said senior author Dr. Kai John Neelsen, assistant professor of protein research at the University of Copenhagen.

Related Links:
University of Copenhagen


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.